References
Referencesarepublicationsthatsupporttheproducts'biologicalactivity.
Engelmanetal(2007)PF00299804,anirreversiblepan-ERBBinhibitor,iseffectiveinlungcancermodelswithEGFRandERBB2mutationsthatareresistanttogefitinib.Cancer.Res.6711924PMID:18089823
Gonzalesetal(2008)AntitumoractivityandpharmacokineticpropertiesofPF-00299804,asecond-generationirreversiblepan-erbBreceptortyrosinekinaseinhibitor.Mol.Cancer.Ther.71880PMID:18606718
Lietal(2017)AROR1-HER3-lncRNAsignallingaxismodulatestheHippo-YAPpathwaytoregulatebonemetastasis.Nat.Cell.Biol.19106PMID:28114269
Keywords:Dacomitinib,supplier,Dacomitinib,ErbB,inhibitors,inhibits,EGFR,ERBB2,ERBB4,potent,irreversible,pan-ErbB,cancer,orally,bioavailable,PF00299804,EGFR,EGFR,TocrisBioscience